Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

This publication has 36 references indexed in Scilit:

• Neuraminidase Inhibitors for Influenza
  New England Journal of Medicine, 2005
• Influenza-Associated Hospitalizations in the United States
  JAMA, 2004
• Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir
  Antimicrobial Agents and Chemotherapy, 2003
• Efficacy of Zanamivir against Avian Influenza A Viruses That Possess Genes Encoding H5N1 Internal Proteins and Are Pathogenic in Mammals
  Antimicrobial Agents and Chemotherapy, 2001
• Inhaled Zanamivir for the Prevention of Influenza in Families
  New England Journal of Medicine, 2000
• Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial
  The Pediatric Infectious Disease Journal, 2000
• Clinical Efficacy and Safety of the Orally Inhaled Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza: a Randomized, Double-blind, Placebo-controlled European Study
  Journal of Infection, 2000
• Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
  The Lancet, 1998
• 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
  Antimicrobial Agents and Chemotherapy, 1993
• Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985.
  American Journal of Public Health, 1987